Celldex Therapeutics (CLDX) Tax Provisions (2017 - 2021)

Celldex Therapeutics' Tax Provisions history runs 4 years deep, the most recent figure standing at -$227000.0 for Q3 2021.

• On a quarterly basis, Tax Provisions changed N/A year-over-year to -$227000.0 in Q3 2021; TTM through Dec 2021 was $673000.0, a 113.62% increase from a year earlier, with the FY2023 full-year figure at -$29.7 million, down 25.91% from the prior year.
• Tax Provisions fell to -$227000.0 in Q3 2021 per CLDX's latest filing, from $900000.0 in the prior quarter.
• Across five years, Tax Provisions topped out at $900000.0 in Q4 2020 and bottomed at -$19.1 million in Q4 2017.
• The 4-year median for Tax Provisions is -$513500.0 (2018), against an average of -$3.8 million.
• Biggest YoY gain for Tax Provisions was 70.44% in 2018; the steepest drop was 70.44% in 2018.
• Year by year, Tax Provisions stood at -$19.1 million in 2017, then surged by 70.44% to -$5.6 million in 2018, then soared by 115.95% to $900000.0 in 2020, then sank by 125.22% to -$227000.0 in 2021.
• Per Business Quant, the three latest CLDX Tax Provisions figures stand at -$227000.0 (Q3 2021), $900000.0 (Q4 2020), and -$200000.0 (Q2 2020).